State Street’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$136M Buy
1,818,186
+45,288
+3% +$2.91M ﹤0.01% 1298
2026
Q1
$99.9M Buy
1,772,898
+43,051
+2% +$2.8M ﹤0.01% 1371
2025
Q4
$139M Sell
1,729,847
-70,882
-4% -$4.76M ﹤0.01% 1169
2025
Q3
$87.8M Sell
1,800,729
-83,254
-4% -$5.15M ﹤0.01% 1406
2025
Q2
$141M Sell
1,883,983
-34,033
-2% -$2.25M 0.01% 1126
2025
Q1
$122M Sell
1,918,016
-28,971
-1% -$1.97M 0.01% 1169
2024
Q4
$152M Buy
1,946,987
+58,494
+3% +$4.7M 0.01% 1092
2024
Q3
$152M Buy
1,888,493
+38,010
+2% +$3.07M 0.01% 1089
2024
Q2
$153M Buy
1,850,483
+18,313
+1% +$1.61M 0.01% 1023
2024
Q1
$156M Buy
1,832,170
+42,534
+2% +$3.34M 0.01% 1021
2023
Q4
$153M Buy
1,789,636
+48,151
+3% +$4.16M 0.01% 1016
2023
Q3
$156M Sell
1,741,485
-12,348
-0.7% -$1.1M 0.01% 902
2023
Q2
$149M Buy
1,753,833
+19,053
+1% +$1.61M 0.01% 973
2023
Q1
$144M Buy
1,734,780
+42,985
+3% +$3.48M 0.01% 965
2022
Q4
$133M Sell
1,691,795
-5,389
-0.3% -$433K 0.01% 989
2022
Q3
$126M Buy
1,697,184
+27,667
+2% +$1.99M 0.01% 975
2022
Q2
$109M Sell
1,669,517
-65,072
-4% -$3.85M 0.01% 1092
2022
Q1
$110M Buy
1,734,589
+43,396
+3% +$2.36M 0.01% 1227
2021
Q4
$89.7M Buy
1,691,193
+29,958
+2% +$1.83M ﹤0.01% 1383
2021
Q3
$117M Sell
1,661,235
-13,719
-0.8% -$866K 0.01% 1144
2021
Q2
$112M Buy
1,674,954
+447,875
+36% +$31.7M 0.01% 1214
2021
Q1
$136M Buy
1,227,079
+5,826
+0.5% +$721K 0.01% 1004
2020
Q4
$145M Sell
1,221,253
-1,016
-0.1% -$109K 0.01% 901
2020
Q3
$107M Sell
1,222,269
-37,953
-3% -$3.32M 0.01% 931
2020
Q2
$113M Sell
1,260,222
-414,668
-25% -$41.9M 0.01% 880
2020
Q1
$167M Buy
1,674,890
+22,624
+1% +$2.45M 0.01% 669
2019
Q4
$190M Sell
1,652,266
-30,216
-2% -$3.66M 0.01% 724
2019
Q3
$212M Sell
1,682,482
-40,900
-2% -$5.19M 0.02% 668
2019
Q2
$207M Buy
1,723,382
+1,715
+0.1% +$169K 0.02% 682
2019
Q1
$151M Buy
1,721,667
+62,609
+4% +$5.69M 0.01% 777
2018
Q4
$166M Sell
1,659,058
-186,003
-10% -$19.5M 0.02% 684
2018
Q3
$211M Buy
1,845,061
+31,634
+2% +$3.27M 0.02% 689
2018
Q2
$163M Buy
1,813,427
+410,039
+29% +$34.6M 0.01% 772
2018
Q1
$103M Buy
1,403,388
+5,877
+0.4% +$403K 0.01% 986
2017
Q4
$81.2M Buy
1,397,511
+63,653
+5% +$3.35M 0.01% 1141
2017
Q3
$59.9M Buy
1,333,858
+2,864
+0.2% +$119K 0.01% 1264
2017
Q2
$52.6M Buy
1,330,994
+62,887
+5% +$2.58M ﹤0.01% 1326
2017
Q1
$51.4M Buy
1,268,107
+97,466
+8% +$3.81M ﹤0.01% 1314
2016
Q4
$47.1M Buy
1,170,641
+86,552
+8% +$3.26M ﹤0.01% 1303
2016
Q3
$39.3M Buy
1,084,089
+64,873
+6% +$2.23M ﹤0.01% 1349
2016
Q2
$29.5M Sell
1,019,216
-11,178
-1% -$338K ﹤0.01% 1480
2016
Q1
$36M Buy
1,030,394
+11,371
+1% +$367K ﹤0.01% 1331
2015
Q4
$32.9M Buy
1,019,023
+22,859
+2% +$741K ﹤0.01% 1397
2015
Q3
$32.2M Sell
996,164
-90,871
-8% -$3.42M ﹤0.01% 1425
2015
Q2
$45M Sell
1,087,035
-49,003
-4% -$2.07M ﹤0.01% 1334
2015
Q1
$51M Sell
1,136,038
-1,725
-0.2% -$72.1K 0.01% 1228
2014
Q4
$42.6M Sell
1,137,763
-7,098
-0.6% -$260K ﹤0.01% 1311
2014
Q3
$40M Sell
1,144,861
-25,387
-2% -$906K ﹤0.01% 1291
2014
Q2
$41.3M Sell
1,170,248
-8,834
-0.7% -$295K ﹤0.01% 1320
2014
Q1
$38.4M Buy
1,179,082
+12,859
+1% +$491K ﹤0.01% 1357
2013
Q4
$49.1M Sell
1,166,223
-9,841
-0.8% -$405K 0.01% 1202
2013
Q3
$46.9M Buy
1,176,064
+1,606
+0.1% +$67.4K 0.01% 1200
2013
Q2
$48.6M Buy
+1,174,458
New +$47.5M 0.01% 1132

Other funds holding HAE

State Street's HAE Position: Q2 2026 in Review

State Street increased its Haemonetics (HAE) stake by 2.6% in Q2 2026, buying an estimated $2.91M and bringing the position to 1,818,186 shares worth $136M. The position accounts for ﹤0.01% of the portfolio, ranked #1298.

State Street first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $212M in Q3 2019. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • State Street held 1,818,186 shares of Haemonetics worth $136M as of Q2 2026.
  • State Street bought 45,288 Haemonetics shares in Q2 2026, an estimated $2.91M.
  • Haemonetics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1298 holding.
  • State Street first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
  • State Street's Haemonetics position peaked at $212M in Q3 2019.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.